{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:07:36Z","timestamp":1793066856819,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41591-021-01584-3","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T11:02:37Z","timestamp":1638788557000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4712-3206","authenticated-orcid":false,"given":"Christian T.","family":"Ruff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyungAh","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred T.","family":"Fiedorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"1584_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","volume":"314","author":"C Emerging Risk Factors","year":"2015","unstructured":"Emerging Risk Factors, C. et al. Association of cardiometabolic multimorbidity with mortality. JAMA 314, 52\u201360 (2015).","journal-title":"JAMA"},{"key":"1584_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/jama.2015.10029","volume":"314","author":"A Menke","year":"2015","unstructured":"Menke, A., Casagrande, S., Geiss, L. & Cowie, C. C. Prevalence of and trends in diabetes among adults in the United States, 1988\u20132012. JAMA 314, 1021\u20131029 (2015).","journal-title":"JAMA"},{"key":"1584_CR3","unstructured":"US Food and Drug Administration. Guidance for industry: diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm071627.pdf (2008)."},{"key":"1584_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7, 776\u2013785 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1584_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31\u201339 (2019).","journal-title":"Lancet"},{"key":"1584_CR6","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker, T. A. et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139, 2022\u20132031 (2019).","journal-title":"Circulation"},{"key":"1584_CR7","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228\u20131239 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1584_CR8","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.clinthera.2013.03.011","volume":"35","author":"RR Henry","year":"2013","unstructured":"Henry, R. R., Logan, D., Alessi, T. & Baron, M. A. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes. Clin. Ther. 35, 634\u2013645 (2013).","journal-title":"Clin. Ther."},{"key":"1584_CR9","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2337\/dc12-2410","volume":"36","author":"RR Henry","year":"2013","unstructured":"Henry, R. R. et al. Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. Diabetes Care 36, 2559\u20132565 (2013).","journal-title":"Diabetes Care"},{"key":"1584_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jdiacomp.2013.12.009","volume":"28","author":"RR Henry","year":"2014","unstructured":"Henry, R. R. et al. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J. Diabetes Complications 28, 393\u2013398 (2014).","journal-title":"J. Diabetes Complications"},{"key":"1584_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/dom.13133","volume":"20","author":"R Henry","year":"2018","unstructured":"Henry, R. et al. Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin. Diabetes Obes. Metab. 20, 638\u2013645 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"1584_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2337\/dc17-1519","volume":"41","author":"RR Henry","year":"2018","unstructured":"Henry, R. R. et al. Clinical impact of ITCA 650, a novel drug-device GLP-1 receptor agonist, in uncontrolled type 2 diabetes and very high baseline HbA(1c): the FREEDOM-1 HBL (high baseline) study. Diabetes Care 41, 613\u2013619 (2018).","journal-title":"Diabetes Care"},{"key":"1584_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2337\/dc17-1306","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock, J. et al. Efficacy and safety of ITCA 650, a novel drug-device GLP-1 receptor agonist, in type 2 diabetes uncontrolled with oral antidiabetes drugs: the FREEDOM-1 trial. Diabetes Care 41, 333\u2013340 (2018).","journal-title":"Diabetes Care"},{"key":"1584_CR14","first-page":"183","volume":"65","author":"J Rosenstock","year":"2016","unstructured":"Rosenstock, J. et al. Superior efficacy of ITCA 650 vs sitagliptin in uncontrolled type 2 diabetes on metformin: the FREEDOM 2 randomized, double-blind, 1-year study. Diabetes 65, 183\u20131 (2016).","journal-title":"Diabetes"},{"key":"1584_CR15","doi-asserted-by":"crossref","unstructured":"Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. 385, 896\u2013907 (2021).","DOI":"10.1056\/NEJMoa2108269"},{"key":"1584_CR16","doi-asserted-by":"crossref","unstructured":"Riley, R. D., Lambert, P. C. & Abo-Zaid, G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340, c221 (2010).","DOI":"10.1136\/bmj.c221"},{"key":"1584_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2307\/2531201","volume":"42","author":"JM Lachin","year":"1986","unstructured":"Lachin, J. M. & Foulkes, M. A. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42, 507\u2013519 (1986).","journal-title":"Biometrics"},{"key":"1584_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/sim.1400","volume":"22","author":"M Rothmann","year":"2003","unstructured":"Rothmann, M. et al. Design and analysis of non-inferiority mortality trials in oncology. Stat. Med. 22, 239\u2013264 (2003).","journal-title":"Stat. Med."},{"key":"1584_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2307\/2530245","volume":"35","author":"PC O\u2019Brien","year":"1979","unstructured":"O\u2019Brien, P. C. & Fleming, T. R. A multiple testing procedure for clinical trials. Biometrics 35, 549\u2013556 (1979).","journal-title":"Biometrics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01584-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T15:04:45Z","timestamp":1643382285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01584-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01584-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.T.R. reports grant support from Boehringer Ingelheim, Daiichi Sankyo, MedImmune and the National Institutes of Health and has received consulting fees from Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, MedImmune, Pfizer, Portola and Anthos. M.B. and F.T.T. are employees of Intarcia Therapeutics, and M.B. owns stock in Intarcia Therapeutics. M.L.O. reports grants from Eisai, AstraZeneca, GlaxoSmithKline, Merck, Amgen, Janssen and The Medicines Company and has received consulting fees from Novartis, Janssen, Amgen and AstraZeneca. M.S.S. reports research grant support from Abbott Laboratories, Amgen, AstraZeneca, Bayer, Critical Diagnostics, Daiichi Sankyo, Eisai, Genzyme, Gilead, GlaxoSmithKline, Intarcia Therapeutics, IONIS, Janssen Research and Development, The Medicines Company, MedImmune, Merck, Novartis, Poxel, Pfizer, Quark Pharmaceuticals, Roche Diagnostics and Takeda and has received consulting fees from Alnylam, Amgen, AstraZeneca, Bristol Myers Squibb, CVS Caremark, Dyrnamix, Esperion, IFM Pharmaceuticals, Intarcia Therapeutics, Ionis, Janssen Research and Development, The Medicines Company, MedImmune, Merck, Moderna, MyoKardia, Novartis and Novo Nordisk. C.T.R., M.L.O., K.I. and M.S.S. are members of the TIMI Study Group, which has received institutional research grant support through Brigham and Women\u2019s Hospital from Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, BRAHMS, Daiichi Sankyo, Eisai, GlaxoSmithKline, Intarcia Therapeutics, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company and Zora Biosciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}